First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy
BJU International · 2024
DOI: 10.1111/bju.16336 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BJU International, 2024. Verfasst von Takafumi Yanagisawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To compare the differential efficacy of first‐line immune checkpoint inhibitor (ICI)‐based combined therapies among patients with intermediate‐ and poor‐risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. Patients and Methods Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first‐line ICI‐based combined therapies. We performed network meta‐analysis (NMA) to compare the outcomes, including progression‐free survival (PFS) and objective response rates (ORRs), in patients with intermediate‐ and poor‐risk mRCC; we also assessed treatment‐related adverse events.
Results
Overall, seven RCTs were included in the meta‐analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72–1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups.
Conclusions
Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first‐line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Urology, Medical University of Silesia, Zabrze, Poland.
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Clinic of Urology and Urological Oncology, Jagiellonian University, Krakow, Poland.
ORCID-Profile: Takafumi Yanagisawa, Tatsushi Kawada, Kensuke Bekku, Ekaterina Laukhtina, Pawel Rajwa, Keiichiro Mori
Zitieren
APA
Yanagisawa, T., Kawada, T., Bekku, K., Laukhtina, E., Rajwa, P., von Deimling, M., Chlosta, M., Quhal, F., Pradere, B., Karakiewicz, P. I., Mori, K., Kimura, T., Shariat, S. F., & Schmidinger, M. (2024). First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy. BJU International. https://doi.org/10.1111/bju.16336
Vancouver
Yanagisawa T, Kawada T, Bekku K, Laukhtina E, Rajwa P, von Deimling M, et al. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy. BJU International. 2024. doi:10.1111/bju.16336
BibTeX
@article{Yanagisawa2024,
author = {Yanagisawa, Takafumi and Kawada, Tatsushi and Bekku, Kensuke and Laukhtina, Ekaterina and Rajwa, Pawel and von Deimling, Markus and Chlosta, Marcin and Quhal, Fahad and Pradere, Benjamin and Karakiewicz, Pierre I and Mori, Keiichiro and Kimura, Takahiro and Shariat, Shahrokh F and Schmidinger, Manuela},
title = {First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy},
journal = {BJU International},
year = {2024},
doi = {10.1111/bju.16336}
}
EUVIMED